The role of glutamate in dementia

  • J. Kornbuber
  • J. Wiltfang
Conference paper
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 53)


Glutamate is an excitatory neurotransmitter, but may also act as an endogenous neurotoxin. There is good evidence for an involvement of the glutamatergic system in the pathophysiology of dementia. The glutamatergic transmission machinery is quite complex and provides a gallery of possible drug targets. There are good arguments both for an agonist and an antagonist strategy. When following the antagonist strategy, the goal is to provide neuroprotective effects via glutamate receptor antagonisms without inhibiting the physiological transmission that is required for learning and memory formation. When following the agonist strategy, the goal is to activate glutamatergic transmission without neurotoxic side effects. Several available antidementia drugs may modulate the glutamatergic transmission.

The pathogenesis of the most frequent type of dementia, i.e. Alzheimer’s disease, is poorly understood. Currently, there is an enormous need for an effective pharmacotherapy that either slows the rate of progression or produces clinically significant improvement in symptoms. This short overview describes the role of the excitatory neurotransmitter glutamate in Alzheimer’s disease. Glutamate is the transmitter used, e.g., in corticocortical association neurons and in intrahippocampal fibers. Glutamatergic mechanisms are involved in fast synaptic transmission as well as in learning and memory processes. But, under certain conditions, glutamate may become a neurotoxin leading to slowly progressive as well as acute neuronal cell loss. These properties of the glutamatergic system led to the hypothesis that there might be a glutamatergic strategy for the treatment of Alzheimer’s disease and also other dementia syndromes (Greenamyre et al., 1985; Greenamyre et al., 1988; Lawlor and Davis, 1992).


NMDA Receptor NMDA Receptor Antagonist Quinolinic Acid Domoic Acid Glutamatergic Transmission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565–571PubMedCrossRefGoogle Scholar
  2. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31: 119–130PubMedCrossRefGoogle Scholar
  3. Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31–39PubMedCrossRefGoogle Scholar
  4. Choi DW (1994) Excitoxicity. In: Meldrum BS (ed) Excitatory amino acid antagonists. Blackwell Scientific Publications, Oxford, pp 216–236Google Scholar
  5. Danysz W, Archer T (1994) Glutamate, learning and dementia — selection of evidence. Amino Acids 7: 147–163CrossRefGoogle Scholar
  6. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies. Neurosci Biobehav Rev 21: 455–468PubMedCrossRefGoogle Scholar
  7. De Boni U, McLachlan DRC (1985) Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons, by glutamate and aspartate. J Neurol Sci 68: 105–118PubMedCrossRefGoogle Scholar
  8. Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Skare S, Fakouhi JD, Herting RL (1992) Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 40: 503–506PubMedGoogle Scholar
  9. Edwards FA (1995) LTP — a structural model to explain the inconsistencies. Trends Neurosci 18: 250–255PubMedCrossRefGoogle Scholar
  10. Esclaire F, Lesort M, Blanchard C, Hugon J (1997) Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res 49: 309–318PubMedCrossRefGoogle Scholar
  11. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampus slices. Br J Pharmacol 117: 689–697PubMedCrossRefGoogle Scholar
  12. Giulian D, Haverkamp LJ, Li J, Karshin W, Yu J, Tom D, Li X, Kirkpatrick JB (1995) Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 27: 119–137PubMedCrossRefGoogle Scholar
  13. Görtelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung/Drug Res 42: 904–913Google Scholar
  14. Greenamyre JT, Penney JB, Young AB, D’Amato CJ, Hicks SP, Shoulson I (1985) Alterations in glutamate binding in Alzheimer’s and Huntington’s disease. Science 227: 1496–1499PubMedCrossRefGoogle Scholar
  15. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988) Glutamate transmission and toxicity in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 12: 421–430PubMedCrossRefGoogle Scholar
  16. Groh D, Rodewald S, Rammsayer T (1996) Experimentelle Studie zum Einfluss des NMDA-Rezeptorenantagonisten Memantine auf Lern-und Gedächtnisfunktionen bei gesunden Probanden. Fortschr Neurol Psychiatrie 64: 144Google Scholar
  17. Gsell W, Strein I, Riederer P (1996) The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm [Suppl] 47: 73–101CrossRefGoogle Scholar
  18. Handelmann GE, Nevins ME, Mueller LL, Arnolde SM, Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Biochem Pharmacol Behav 34: 823–828CrossRefGoogle Scholar
  19. Hood WF, Compton RP, Monahan JB (1989) D-Cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist properties. Neurosci Lett 98: 91–95PubMedCrossRefGoogle Scholar
  20. Ingvar M, Ambros Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, Schehr RS, Lynch G (1997) Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146: 553–559PubMedCrossRefGoogle Scholar
  21. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325: 529–531PubMedCrossRefGoogle Scholar
  22. Klegeris A, McGeer PL (1997) beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res 49: 229–235PubMedCrossRefGoogle Scholar
  23. Kornhuber J, Weiler M (1995) Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (eds) Schizophrenia — an integrated view. Alfred Benzon Symposium 38. Munksgaard, Copenhagen, pp 314–325Google Scholar
  24. Kornhuber J, Weiler M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144PubMedCrossRefGoogle Scholar
  25. Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590PubMedCrossRefGoogle Scholar
  26. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-aminoadamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300CrossRefGoogle Scholar
  27. Kornhuber J, Weiler M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104Google Scholar
  28. Kornhuber J, Retz W, Sitzmann L, Schmidtke A, Herbert MK (1996) The NMDA-receptor antagonist memantine is not psychotomimetic in young healthy volunteers. Soc Neurosci Abstr 22: 178Google Scholar
  29. Krömer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, Kornhuber J (1998) Quantitative analysis of the structural requirements for blockade of the NMDA receptor at the PCP binding site. J Med Chem 41: 393–400CrossRefGoogle Scholar
  30. Lawlor BA, Davis KL (1992) Does modulation of glutamatergic function represent a viable therapeutic stragegy in Alzheimer’s disease? Biol Psychiatry 31: 337–350PubMedCrossRefGoogle Scholar
  31. Li S, Mallory M, Alford M, Tanaka S, Masliah E (1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56: 901–911PubMedCrossRefGoogle Scholar
  32. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 40: 759–766PubMedCrossRefGoogle Scholar
  33. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376–389PubMedGoogle Scholar
  34. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid — protection by MK-801 and memantine. Eur J Pharmacol 296: 1–8PubMedCrossRefGoogle Scholar
  35. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989) D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 34: 649–653PubMedCrossRefGoogle Scholar
  36. Olney JW (1978) Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW, McGeer PL (eds) Kainic acid as a tool in neurobiology. Raven Press, New York, pp 95–121Google Scholar
  37. Pantev M, Ritter R, Görtelmeyer R (1993) Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol 6: 103–117Google Scholar
  38. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258PubMedCrossRefGoogle Scholar
  39. Perl TM, Bedard L, Kosatsky T, Hockin JC, Todd ECD, Remis RS (1990) An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 25: 1775–1780CrossRefGoogle Scholar
  40. Pomara N, Mendels PA, LeWitt PA, Reisberg B, Nair N, Dysken M, Wood J, Fakouhi TD, Herting RL (1991) Multicenter trial of milacemide in the treatment of Alzheimer’s disease. Biol Psychiatry 29: 701SGoogle Scholar
  41. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN (1994) D-Cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 8: 198–205PubMedCrossRefGoogle Scholar
  42. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1991) Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet 338: 1022–1023PubMedCrossRefGoogle Scholar
  43. Schuster GM, Schmidt WJ (1992) D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur J Pharmacol 224: 97–98PubMedCrossRefGoogle Scholar
  44. Schwartz BL, Hashtroudi S, Herting RL, Handerson H, Deutsch SI (1991) Glycine prodrug facilitates memory retrieval in humans. Neurology 41: 1341–1343PubMedCrossRefGoogle Scholar
  45. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR (1990) Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 322: 1781–1787PubMedCrossRefGoogle Scholar
  46. Thompson LT, Moskal JR, Disterhoft JF (1992) Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359: 638–641PubMedCrossRefGoogle Scholar
  47. Tymianski M, Charlton MP, Carlen PL, Tator CH (1993) Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 13: 2085–2104PubMedGoogle Scholar
  48. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510: 158–160PubMedCrossRefGoogle Scholar
  49. Zajaczkowski W, Danysz W (1997) Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Pharmacol Biochem Behav 56: 21–29PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • J. Kornbuber
    • 1
  • J. Wiltfang
    • 1
  1. 1.Department of PsychiatryUniversity of GöttingenGöttingenFederal Republic of Germany

Personalised recommendations